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Abstract Dexamethasone and transforming growth factor-L
(TGF-L) show contrary e¡ects on di¡erentiation of adipocytes.
Dexamethasone stimulates adipocyte di¡erentiation whereas
TGF-L inhibits it. In the present study, we investigated whether
dexamethasone could reverse the TGF-L-mediated inhibition of
preadipocyte di¡erentiation. Primary rat preadipocytes, ob-
tained from Sprague^Dawley rats, were pretreated with dexa-
methasone in the presence or absence of TGF-L, prior to the
induction of di¡erentiation. Co-treatment of dexamethasone and
TGF-L before inducing di¡erentiation reversed the TGF-L-
mediated inhibition of preadipocyte di¡erentiation. In order to
elucidate the mechanism by which dexamethasone reversed the
e¡ect of TGF-L on the inhibition of preadipocyte di¡erentiation,
the expression of CCAAT/enhancer binding protein-K (C/
EBPK) and peroxisome proliferator-activated receptor Q (PPARQ)
was examined. Dexamethasone increased C/EBPK and PPARQ
expression in the absence of TGF-L and also recovered the
TGF-L-mediated suppression of C/EBPK expression in preadi-
pocytes. Its e¡ect was sustained in di¡erentiated adipocytes as
well. However, those e¡ects were not observed in 3T3-L1 pre-
adipocytes or di¡erentiated adipocytes. These results indicate
that dexamethasone reverses the TGF-L-mediated suppression
of adipocyte di¡erentiation by regulating the expression of C/
EBPK and PPARQ, which is dependent on the cellular context.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Adipogenesis is a multistep process that ful¢lls the need for
the storage of excess energy. Experiments using various cell
culture systems, which include 3T3-L1 [1], PAZ6 [2] and a
primary preadipocyte culture [3], revealed that several tran-
scriptional factors play major roles in adipocyte di¡erentia-
tion. CCAAT/enhancer binding proteins (C/EBPs), nuclear
hormone receptor, peroxisome proliferator-activated receptor
Q (PPARQ), and adipocyte determination and di¡erentiation
factor-1/sterol regulatory element binding protein-1c are all
major transcription factors associated with the adipocyte dif-
ferentiation process.
Transforming growth factor-L (TGF-L) exhibits potent ef-
fects on a wide variety of cell types. It inhibits the prolifer-
ation of epithelial cell lines [4], while stimulating the prolifer-
ation of some mesenchymal cells [5,6]. The e¡ects of TGF-L
on the di¡erentiation of various tissues of mesenchymal and
epithelial origin include both the prevention and induction of
expression of speci¢c phenotypes. TGF-L is able to block the
di¡erentiation of preadipocyte cell lines, such as 3T3-L1 [7,8],
TA1 cells [9] and primary cultures of preadipocytes [10,11]. It
inhibits the di¡erentiation of 3T3-L1 preadipocytes by de-
creasing C/EBPK and PPARQ, which are critical for adipo-
genesis [12,13].
Dexamethasone and isobutylmethylxanthine, which are
both important adipogenic inducers, induce the expression
of C/EBPN and C/EBPL, respectively [14]. The expression of
both C/EBPN and C/EBPL is known to increase that of
C/EBPK and PPARQ [14,15], which in turn stimulates the
di¡erentiation of 3T3-L1 preadipocytes. The e¡ect of dexa-
methasone on the enhancement of adipocyte di¡erentiation
is dependent on the cellular context. For example, it inhibits
the di¡erentiation of 3T3-F442A preadipocytes [16], although
dexamethasone is routinely used for the di¡erentiation of pre-
adipocyte cell lines, such as 3T3-L1 and TA1.
In this study, we investigated the e¡ects of the co-treatment
of dexamethasone and TGF-L on primary rat preadipocyte
di¡erentiation, as dexamethasone stimulates the di¡erentia-
tion of adipocytes and TGF-L inhibits it.
2. Materials and methods
2.1. Animals and cells
Male Sprague^Dawley (SD) rats (Dae Han Bio Link), 8^12 weeks
of age, were allowed to acclimatize to handling for 4 days under
standard conditions of 12 h light per day, prior to the experiments.
Food and water were provided ad libitum. 3T3-L1 preadipocytes were
obtained from ATCC, and maintained in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS; Life
Technologies).
2.2. Preparation and di¡erentiation of primary rat preadipocytes
The preadipocytes were prepared from adipose tissue using a modi-
¢ed method [17,18]. The epididymal adipose deposits from male SD
rats, aged 8^10 weeks, were quickly removed. The epididymal fat
depots were washed with phosphate-bu¡ered saline (PBS), cut into
2-mm pieces, and then mixed with 10 ml of collagenase bu¡er (2 mg/
ml, type II; Sigma). After incubating for 50 min at 37‡C in a rocking
platform shaker, the 15-ml conical tubes, containing digested tissues,
were centrifuged at 500 rpm for 1 min to remove the £oating mature
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adipocytes. For the preparation of the preadipocytes, the infranatants
were centrifuged at 2000 rpm for 5 min. The resulting pellet was
resuspended in a hemolytic bu¡er (Sigma), incubated at room temper-
ature for 3 min, washed twice with PBS, and then resuspended in
DMEM supplemented with 10% FBS. The prepared preadipocytes,
or 3T3-L1 preadipocyte cell line, were plated at a concentration of
1U106 cells per well, in 6-well plates, and cultured for 3 days. Di¡er-
entiation was induced by the addition of DMEM supplemented with
0.5 M isobutylmethylxanthine, 2 WM dexamethasone, 1.7 WM insulin
and 10% FBS. The induction medium was removed 2 days after in-
cubation. After an additional 2 days incubation with DMEM supple-
mented with 10% FBS and 1.7 WM insulin, the medium was replaced
every 2 days with DMEM supplemented with 10% FBS. At the time
of the experiments more than 70% of the primary culture cells, and
90% of the 3T3-L1 cells, were ¢lled with multiple lipid droplets. The
lipid accumulations in the di¡erentiated adipocytes were assessed
through staining of the neutral fats and cholesterol esters using Oil
Red O dye (Sigma). In brief, the di¡erentiated adipocytes were ¢xed
in 4% formaldehyde for 10 min, and then stained for 30 min with the
Oil Red O dye dissolved in isopropanol. The stained adipocytes were
washed with PBS, and then the quanti¢cation of the lipid staining was
measured by the addition of 1 ml isopropanol to extract the dye, the
absorbance was measured at 420 nm [19].
2.3. Dexamethasone and TGF-L treatment
The prepared preadipocytes were incubated with 2 WM dexametha-
sone, in the presence or absence of TGF-L (1 ng/ml), for 3 days. The
medium was then removed and the total RNA was isolated. For
preadipocyte di¡erentiation, the preadipocytes treated with dexame-
thasone, in either the presence or absence of TGF-L, were subjected to
di¡erentiation. On day 8, the total RNA was isolated and subjected to
Northern blot analysis.
2.4. Preparation of cDNA fragment
To prepare cDNA probe for Northern analysis, the following prim-
er pairs were designed and used in the reverse transcription polymer-
ase chain reaction, using rat adipocyte cDNA as a template: C/EBPK,
5P-GAATCTCCTAGTCCTGGCTC-3P and 5P-GATGAGAACAGC-
AACGAGTAC-3P ; PPARQ, 5P-TGGGGATGTCTCACAATGCCA-
3P and 5P-TTCCTGTCAAGATCGCCCTCG-3P ; fatty acid binding
protein (aP2), 5P-GACCTGGAAACTCGTCTCCA-3P and 5P-CATG-
ACACATTCCACCACCA-3P. The resulting bands were cloned into a
pGEM-T vector (Promega) and sequenced.
2.5. Northern blot analysis
The total RNA from the primary rat adipocytes or 3T3-L1 cells was
prepared using RNAzol B (Tel-Test), electrophoresed in a 3% form-
aldehyde gel, and transferred onto a nylon membrane using a turbo
blotter (Schleicher and Schuell). To estimate the amount of RNA
loading, the transferred membrane was photographed. 32P-labeled
cDNA probes were prepared using a High Prime DNA labeling kit
(Roche Applied Science) and used for sequential hybridizations. After
each hybridization, the membrane was washed with 0.1USSC, 0.05%
SDS at 50‡C and exposed to X-ray ¢lm for 18 h at 380‡C using an
intensifying screen. The membrane was stripped thoroughly by boiling
in 0.01% SDS for 5 min following the hybridization with each probe.
2.6. Statistical analysis
The data are presented as the meansQS.E.M., and were statistically
analyzed using the unpaired t-test. A di¡erence was considered sig-
ni¢cant with a P value of 6 0.05.
3. Results
3.1. TGF-L enhances adipocyte proliferation and suppresses
di¡erentiation
The preadipocytes isolated from the epididymal adipose
deposits of SD rats were treated with TGF-L prior to the
induction of di¡erentiation. After incubation for 3 days, the
number of preadipocytes was observed to increase compared
with control (Fig. 1A), indicating that TGF-L stimulates the
proliferation of preadipocytes. We also examined the e¡ect of
dexamethasone on TGF-L-stimulated proliferation of preadi-
pocytes. Dexamethasone suppressed the proliferation of pre-
adipocytes induced by TGF-L (Fig. 1B).
To examine the roles of TGF-L in the di¡erentiation of
preadipocytes, the isolated preadipocytes were incubated
with TGF-L for 3 days. The culture medium was replaced
with the di¡erentiation medium, and the di¡erentiation pro-
cess was initiated as described in Section 2. On day 8 after the
induction of di¡erentiation, the di¡erentiated adipocytes were
stained with Oil Red O dye or photographed. The pretreat-
ment with TGF-L signi¢cantly suppressed the di¡erentiation
of the preadipocytes (Fig. 1A).
3.2. Dexamethasone reverses TGF-L-mediated suppression of
preadipocyte di¡erentiation
In an e¡ort to ¢nd factors that can reverse the TGF-L
suppressing activity of preadipocyte di¡erentiation, preadipo-
cytes were treated with linoleic acid or dexamethasone, in the
presence or absence of TGF-L, prior to the induction of di¡er-
entiation, as they are known to enhance preadipocyte di¡er-
entiation. After 3 days of treatment di¡erentiation was in-
Fig. 1. The e¡ects of TGF-L on the proliferation and di¡erentiation of primary rat preadipocytes. A: Preadipocytes isolated from epididymal
adipose deposits were plated in 6-well plates (1U106 cells per well), treated with 1 ng/ml of TGF-L for 3 days, and then photographed. Di¡er-
entiation was induced after the treatment with TGF-L for 3 days. On day 8 after the initiation of di¡erentiation, the adipocytes were photo-
graphed. B: Preadipocytes isolated from epididymal adipose deposits were plated in 12-well plates (1U105 cells per well), treated with 1 ng/ml
of TGF-L in the presence or absence of dexamethasone (1037 M) for 3 days, and then cell number was counted. All values are represented as
the meansQS.E.M. of triplicates. *P6 0.05 compared to the TGF-L-treated sample.
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duced. The di¡erentiated adipocytes were evaluated with Oil
Red O staining and the stained dye was extracted with iso-
propanol. Dexamethasone was found to signi¢cantly increase
the di¡erentiation of the preadipocytes (P6 0.01), whereas
linoleic acid mediated an increase of di¡erentiation, but this
was not signi¢cant statistically (P6 0.1) compared with the
control. Pretreatment with TGF-L completely inhibited the
di¡erentiation of the preadipocytes. Interestingly, co-treat-
ment with dexamethasone and TGF-L reversed the TGF-L-
induced inhibition of di¡erentiation (P6 0.01) compared to
TGF-L treatment alone, but co-treatment with linoleic acid
did not (Fig. 2A). This implies that the signal pathway asso-
ciated with TGF-L-mediated inhibition of preadipocyte di¡er-
entiation can be a¡ected by dexamethasone during the pre-
adipocyte di¡erentiation process.
To determine the optimal concentration of dexamethasone
for reversing the TGF-L-mediated suppression of preadipo-
cyte di¡erentiation, various concentrations of dexamethasone
were used in the treatments in the presence of TGF-L.
As shown in Fig. 2B, dexamethasone (1036^1038 M) sig-
ni¢cantly reversed the TGF-L-mediated inhibition of preadi-
pocyte di¡erentiation compared to TGF-L alone (P6 0.01),
but dexamethasone did not reverse the e¡ects of TGF-L at
the concentration of 1039 M (P6 0.2). This means that a
physiological concentration of dexamethasone is able to re-
verse the TGF-L-mediated suppression of preadipocytes.
In order to ¢nd if the dexamethasone is able to inhibit the
TGF-L e¡ect, even if the TGF-L is added 1 day before the
treatment with dexamethasone, TGF-L was incubated for 1
day and the dexamethasone added without changing the me-
dium. On day 8 of the di¡erentiation, the di¡erentiated adi-
pocytes were measured by Oil Red O staining. Although
TGF-L was added 1 day before the dexamethasone treatment,
it still e¡ectively reversed the TGF-L-mediated suppression of
the di¡erentiation, with the exception of a concentration of
1039 M (Fig. 2C). Both results indicate that dexamethasone is
e¡ective enough to the reverse TGF-L-mediated suppression
of di¡erentiation, regardless of pretreatment or co-treatment
with TGF-L, and that the TGF-L e¡ect is not reversible, as
the di¡erentiation was also inhibited when the di¡erentiation
was induced in the absence of TGF-L.
3.3. Dexamethasone enhances expression of C/EBPK in
preadipocytes and adipocytes
To understand the molecular mechanism of the dexametha-
sone e¡ect on TGF-L-induced suppression of adipocyte di¡er-
entiation, the expression of C/EBPK and PPARQ was analyzed
using Northern blot analysis, as C/EBPK and PPARQ are
known to be powerful transcription factors involved in the
regulation of adipocyte di¡erentiation. Preadipocytes, isolated
from SD rats, were incubated with dexamethasone in the
presence or absence of TGF-L for 3 days. The total RNA
was isolated from the preadipocytes before the induction
of di¡erentiation. Dexamethasone increased the levels of
C/EBPK and PPARQ mRNA, and co-treatment with dexa-
methasone and TGF-L recovered the level of C/EBPK
mRNA expression suppressed by TGF-L alone. This means
that dexamethasone was able to reverse the TGF-L-mediated
suppression of C/EBPK mRNA expression. Meanwhile, the
co-treatment with dexamethasone and TGF-L suppressed
dexamethasone-induced PPARQ mRNA expression at a con-
centration of 1 ng/ml TGF-L (Fig. 3A).
Next, we wondered whether this e¡ect could be sustained
during the di¡erentiation process. Therefore, we performed
the same treatment on preadipocytes for 3 days, after which
the di¡erentiation was initiated as described in Section 2. On
day 8 of the di¡erentiation, the total RNA was isolated.
Dexamethasone alone increased the C/EBPK mRNA expres-
sion, and the co-treatment with TGF-L reversed the TGF-L-
mediated inhibition in di¡erentiated adipocytes. The expres-
sion patterns for PPARQ mRNA were similar to those of
C/EBPK (Fig. 3B). These results indicate that pretreatment
with dexamethasone and TGF-L a¡ects the whole process of
adipocyte di¡erentiation through the induction of C/EBPK
and PPARQ mRNA expression. We also examined the expres-
sion of aP2 mRNA as a di¡erentiation marker. Interestingly,
dexamethasone increased aP2 mRNA expression, even in pre-
adipocytes where no lipid ¢lling was observed.
Fig. 2. The e¡ects of dexamethasone and TGF-L on preadipocyte
di¡erentiation. A: Preadipocytes isolated from epididymal adipose
deposits were plated in 12-well plates (2U105 cells per well), treated
with 30 WM linoleic acid, 1037 M dexamethasone, and 1 ng/ml
TGF-L for 3 days, and then di¡erentiation was induced for 8 days.
Oil Red O staining was used to evaluate the di¡erentiation, and the
absorbance was measured. **P6 0.01 compared with the control.
LA, linoleic acid; Dex, dexamethasone. B: Dexamethasone reverses
the TGF-L-mediated suppression of preadipocyte di¡erentiation.
Preadipocytes isolated from epididymal adipose deposits were plated
in 12-well plates (2U105 cells per well), treated with 1 ng/ml of
TGF-L in the presence or absence of various concentrations of
dexamethasone for 3 days (co-treatment) or (C) treated with 1 ng/ml
TGF-L for 1 day, with various concentrations of dexamethasone
added, and incubated for an additional 2 days (pretreatment). After
8 days of the di¡erentiation process, Oil Red O staining was used
to evaluate the di¡erentiation, and the absorbance was measured.
All values are represented as the meansQS.E.M. of duplicates. Data
shown are representative of one of three independent experiments.
*P6 0.05, **P6 0.01 compared to the TGF-L-treated sample.
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3.4. Dexamethasone did not enhance expression of C/EBPK in
3T3-L1
Next, we examined whether dexamethasone could reverse
the TGF-L-suppressed 3T3-L1 preadipocyte di¡erentiation.
TGF-L- and/or dexamethasone-treated 3T3-L1 preadipocytes
were di¡erentiated. The degree of di¡erentiation was eval-
uated with Oil Red O staining. Unlike in the primary rat
adipocytes, the co-treatment with dexamethasone and TGF-
L did not reverse the TGF-L-mediated suppression of the 3T3-
L1 preadipocyte di¡erentiation compared to the control or the
dexamethasone-treated 3T3-L1 preadipocytes, although TGF-
L alone inhibited the di¡erentiation of the 3T3-L1 preadipo-
cytes (Fig. 4A). Thus, we examined the expression of C/EBPK
mRNA. The 3T3-L1 preadipocyte cell line was treated with
TGF-L and/or dexamethasone, and incubated for 3 days. The
total RNA was isolated from the preadipocytes before the
induction of di¡erentiation, and subjected to Northern blot
analysis. The treatments induced no expression of C/EBPK
mRNA in 3T3-L1 preadipocytes, with no expression of aP2
mRNA, as a di¡erentiation marker (Fig. 4B). To determine
the expression of C/EBPK mRNA in di¡erentiated 3T3-L1
adipocytes, TGF-L- and/or dexamethasone-treated 3T3-L1
preadipocytes were di¡erentiated. On day 8 of di¡erentiation,
the total RNA was isolated, and Northern analysis per-
formed. Although TGF-L suppressed the expression of
C/EBPK and aP2 mRNA, co-treatment with dexamethasone
and TGF-L did not recover the TGF-L-mediated inhibition of
either expression (Fig. 4C). Taken together with the primary
rat preadipocyte data, the TGF-L-induced suppression of
adipocyte di¡erentiation is mediated by down-regulation of
C/EBPK, and dexamethasone reverses the TGF-L e¡ect
through its induction.
4. Discussion
Glucocorticoids and TGF-L play an important role in de-
termining the di¡erentiation and function of adipocytes. The
e¡ect of glucocorticoids on the promotion of adipocyte di¡er-
entiation has been studied in several cell culture systems [20^
23], although dexamethasone inhibits the di¡erentiation of the
3T3-F442A preadipocyte cell line [16]. TGF-L is known to
inhibit the adipogenic conversion of 3T3-L1 cells [7,8], rat
perirenal [24] and human preadipocytes [11]. Therefore, we
thought that glucocorticoids might interact with TGF-L in
the process of preadipocyte di¡erentiation. However, no de-
tailed analyses of the e¡ects of glucocorticoids on TGF-L-
inhibited adipogenic di¡erentiation have been performed. In
this study, we addressed this issue.
Two families of transcription factors, C/EBPs and PPARs,
play major roles in the di¡erentiation of preadipocytes, and
are induced by various adipogenic inducers, including dexa-
methasone, isobutylmethylxanthine, long-chain fatty acids
and prostanoids [14,25,26]. The e¡ects of dexamethasone on
adipocyte di¡erentiation vary depending on the cell line. For
instance, dexamethasone promotes di¡erentiation in 3T3-L1
preadipocytes and is required during the early stages of di¡er-
entiation [14]. In contrast, the di¡erentiation of the 3T3-
F442A preadipocyte cell line is inhibited by dexamethasone
[27]. In our system, dexamethasone enhanced the di¡erentia-
tion of primary rat preadipocytes isolated from the epididy-
mal fat depots of SD rats. In addition, treatment with dexa-
methasone reversed the TGF-L-inhibited adipogenic di¡eren-
tiation.
In 3T3-L1 cells, dexamethasone increases the expression of
C/EBPN involved in the early stages of adipocyte di¡erentia-
Fig. 3. The e¡ect of dexamethasone on the TGF-L-mediated suppression of preadipocyte di¡erentiation. A: Preadipocytes isolated from epidi-
dymal adipose deposits were plated in 6-well plates (6U105 cells per well), treated with TGF-L in the presence or absence of 1037 M dexa-
methasone for 3 days. The total RNA was isolated and subjected to Northern blot analysis. B: For the analysis of di¡erentiated adipocytes,
treated preadipocytes were di¡erentiated for 8 days, and the total RNA was isolated. The transferred blot was photographed and used as an
equal loading control. Data shown are representative of one of two independent experiments.
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tion. The expression of either C/EBPL or C/EBPN increases
the expression of C/EBPK, which in turn stimulates the ¢nal
process of di¡erentiation through the induction of di¡erentia-
tion marker genes [14,28]. This means that the expression of
C/EBPK begins after the induction of di¡erentiation. In rat
preadipocytes, however, C/EBPK expression was observed in
preadipocytes, and was induced by treatment with dexametha-
sone before the induction of di¡erentiation, whereas neither
the control nor the treatment with dexamethasone showed C/
EBPK expression in 3T3-L1 preadipocytes. These data are in
line with those for porcine preadipocytes [29], where dexa-
methasone increases the C/EBPK-positive cells before the in-
duction of di¡erentiation [3]. This implies that the expression
of C/EBPK could begin before the induction of di¡erentiation,
and is dependent on the cellular context and that C/EBPK
could play some roles, at least, in primary rat preadipocytes
prior to the initiation of di¡erentiation.
The adipocyte-speci¢c aP2 is known as a marker for di¡er-
entiation-dependent adipocyte proteins [30] and is increased
during the di¡erentiation process of porcine stromal-vascular
cells [31], but we showed that aP2 expression was induced by
dexamethasone in primary rat adipocytes, and the induced
level was sustained until after di¡erentiation. It is known
that promoters from adipocyte-speci¢c genes, such as GLUT4
or SCD1, and the aP2 genes in 3T3-L1 cells are transactivated
by C/EBPs, including C/EBPK [32,33]. Therefore, the dexa-
methasone-induced C/EBPK may enhance the expression of
aP2 mRNA in primary rat preadipocytes. In addition, PPARQ
may also be involved in the increase of aP2 in dexameth-
asone-treated primary rat preadipocytes, as PPARQ is known
to induce the expression of aP2 mRNA in primary human
monocytes and the monocytic cell line THP-1 [34], and human
adipocytes [35]. This is the ¢rst report detecting aP2 mRNA
induced by dexamethasone in primary rat preadipocytes.
Although aP2 is known as an adipocyte di¡erentiation
marker, and functions as a carrier for the cellular uptake
and intracellular transport of fatty acids, the function of the
dexamethasone-induced aP2 in primary rat adipocytes re-
mains to be elucidated.
TGF-L causes a rapid decrease in the expression of adipose
genes when added to fully di¡erentiated adipocytes in TA1
preadipocytes [9]. Exposure to TGF-L, prior to the induction
of di¡erentiation, blocks the di¡erentiation of 3T3-L1 preadi-
pocytes, but not after the induction of di¡erentiation [8]. In
our primary rat preadipocyte culture system, TGF-L inhibited
the di¡erentiation of preadipocytes through the down-regula-
tion of C/EBPK and PPARQ, and dexamethasone induced the
expression of both genes, and also recovered the TGF-L-medi-
ated suppression of C/EBPK and PPARQ mRNA expression.
In turn, dexamethasone reversed the TGF-L-mediated block
of preadipocyte di¡erentiation through the increase of
C/EBPK and PPARQ mRNA expression suppressed by the
TGF-L.
There is a possible mechanism by which dexamethasone
reverses TGF-L-mediated suppression of C/EBPK and PPARQ
mRNA expression. Glucocorticoid receptor (GR) binds to the
activation domain of Smad3 and blocks the transcription of
Smad3-mediated target genes [36]. It may be possible that
interaction between GR and Smad3 might block recruitment
of transcriptional co-repressors such as HDAC and TGIF
[37]. Thus, GR could reverse Smad3-mediated suppression
of target gene transcription by TGF-L. However, this e¡ect
is dependent on cellular context, since with 3T3-L1, dexa-
methasone failed to induce C/EBPK mRNA expression in
the absence of TGF-L and recover the C/EBPK mRNA ex-
pression that had been inhibited by TGF-L. Since primary
cells may re£ect an in vivo context better than aneuploid
cell lines, the fact that dexamethasone reversed the TGF-L-
mediated block of primary rat preadipocyte di¡erentiation has
signi¢cant physiological implications. That is, TGF-L mRNA
and protein, the inhibitor of adipocyte di¡erentiation, are
paradoxically increased in the adipose tissue of two di¡erent
strains of genetically obese mice, ob/ob and db/db, compared
with their lean controls [38], but elevated TGF-L may not
inhibit the di¡erentiation of adipocytes, since adult ob/ob
mice show an increased secretion of corticosteroids [39], which
could inhibit the TGF-L-mediated block of adipocyte di¡er-
entiation. Meanwhile, an increase in TGF-L stimulates the
proliferation of preadipocytes, leading to the expansion of
the adipose mass in the obese model.
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Fig. 4. The e¡ect of dexamethasone and TGF-L on 3T3-L1 preadi-
pocyte di¡erentiation. A: 3T3-L1 preadipocytes were plated in 6-
well plates (6U105 cells per well), treated with 1 ng/ml TGF-L in
the presence or absence of 1037 M dexamethasone for 3 days, then
di¡erentiation was induced. On day 8 of di¡erentiation, the di¡eren-
tiated adipocytes were stained with Oil Red O and then photo-
graphed. B: 3T3-L1 preadipocytes were plated in 6-well plates
(6U105 cells per well), treated with 1 ng/ml TGF-L in the presence
or absence of 1037 M dexamethasone for 3 days. The total RNA
was isolated and subjected to Northern blot analysis. C: For the
analysis of the di¡erentiated adipocytes, treated preadipocytes were
di¡erentiated for 8 days, then the total RNA was isolated. The
transferred blot was photographed and used as an equal loading
control.
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